EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors

Jiayi Shen iD, Jieman Lin, Anzhi Li, Yunyi Kong, Sheng Chen, Gonghui Li, Yongdong Li

Drug Development Research · 2026

DOI: 10.1002/ddr.70206 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2026. Verfasst von Jiayi Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Province Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi, PR China. Hauptthemen laut MEDLINE: Syk Kinase, Protein Kinase Inhibitors, Drug Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 113 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Spleen tyrosine kinase (SYK), a non‐receptor tyrosine kinase, serves as a pivotal regulator in multiple intracellular signaling pathways, particularly those involved in immune responses. Dysregulated SYK activation has been strongly implicated in the pathogenesis of various hematological malignancies and autoimmune disorders, making it an attractive therapeutic target. Consequently, significant progress has been made in developing SYK inhibitors as a targeted treatment strategy. This article comprehensively reviews recent advances in SYK inhibitor research, focusing on their therapeutic potential in autoimmune diseases and hematologic cancers. Furthermore, we highlight representative SYK inhibitors, discuss their clinical applications, outline current challenges, and future directions in this evolving field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syk KinaseProtein Kinase InhibitorsDrug DesignHumansAnimalsAutoimmune DiseasesHematologic NeoplasmsSignal Transduction

Stichwörter der Autor:innen

autoimmune diseaseshematological malignanciesinhibitorsspleen tyrosine kinase (SYK)

Substanzen

Syk KinaseProtein Kinase InhibitorsSYK protein, human

Autor:innen und Institutionen

  • Jiangxi Province Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, Jiangxi, PR China.
  • Jiangxi Chiralsyn Biological Medicine Co. LTD, Ganzhou, Jiangxi, China.
  • Ganzhou General Inspection and Testing Institute, Ganzhou, Jiangxi, China.

ORCID-Profile: Jiayi Shen

Zitieren

APA

Shen, J., Lin, J., Li, A., Kong, Y., Chen, S., Li, G., & Li, Y. (2026). Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors. Drug Development Research. https://doi.org/10.1002/ddr.70206

Vancouver

Shen J, Lin J, Li A, Kong Y, Chen S, Li G, et al. Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors. Drug Development Research. 2026. doi:10.1002/ddr.70206

BibTeX
@article{Shen2026,
  author = {Shen, Jiayi and Lin, Jieman and Li, Anzhi and Kong, Yunyi and Chen, Sheng and Li, Gonghui and Li, Yongdong},
  title = {Recent Progress of Molecular Design and Activities of Spleen Tyrosine Kinase (SYK) Inhibitors},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70206}
}
Kostenlos starten →